Contrasting Reviva Pharmaceuticals (NASDAQ:RVPH) & Enliven Therapeutics (NASDAQ:ELVN)

Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) and Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

Insider and Institutional Ownership

95.1% of Enliven Therapeutics shares are owned by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. 25.9% of Enliven Therapeutics shares are owned by insiders. Comparatively, 8.9% of Reviva Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Enliven Therapeutics and Reviva Pharmaceuticals’ net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Enliven Therapeutics and Reviva Pharmaceuticals”s top-line revenue, earnings per share and valuation.

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for Enliven Therapeutics and Reviva Pharmaceuticals, as provided by MarketBeat.com.

Enliven Therapeutics currently has a consensus price target of $41.20, indicating a potential upside of 107.56%. Reviva Pharmaceuticals has a consensus price target of $3.86, indicating a potential upside of 525.45%. Given Reviva Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than Enliven Therapeutics.

Volatility and Risk

Enliven Therapeutics has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500. Comparatively, Reviva Pharmaceuticals has a beta of -0.02, indicating that its share price is 102% less volatile than the S&P 500.

Summary

Reviva Pharmaceuticals beats Enliven Therapeutics on 7 of the 12 factors compared between the two stocks.

About Enliven Therapeutics

(Get Free Report)

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

About Reviva Pharmaceuticals

(Get Free Report)

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.